Last reviewed · How we verify
BAT1806
BAT1806 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.
BAT1806 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).
At a glance
| Generic name | BAT1806 |
|---|---|
| Also known as | Actemra(EU-licensed), Actemra(US-licensed) |
| Sponsor | Bio-Thera Solutions |
| Drug class | Bispecific antibody; PD-1/TGF-β inhibitor |
| Target | PD-1 and TGF-β |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking PD-1, BAT1806 relieves immune checkpoint inhibition on T cells. Simultaneously, its binding to TGF-β neutralizes an immunosuppressive cytokine abundant in tumors, further promoting T cell activation and infiltration. This dual mechanism aims to overcome resistance to single-agent PD-1 inhibition.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (in development)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Infusion reactions
Key clinical trials
- A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants (PHASE1)
- A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects (PHASE1)
- Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects (PHASE1)
- Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAT1806 CI brief — competitive landscape report
- BAT1806 updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI